These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. N-Benzyladriamycin-14-valerate (AD 198) cytotoxicty circumvents Bcr-Abl anti-apoptotic signaling in human leukemia cells and also potentiates imatinib cytotoxicity. Lothstein L; Savranskaya L; Sweatman TW Leuk Res; 2007 Aug; 31(8):1085-95. PubMed ID: 17187856 [TBL] [Abstract][Full Text] [Related]
8. Population pharmacokinetics of imatinib mesylate and its metabolite in children and young adults. Menon-Andersen D; Mondick JT; Jayaraman B; Thompson PA; Blaney SM; Bernstein M; Bond M; Champagne M; Fossler MJ; Barrett JS Cancer Chemother Pharmacol; 2009 Jan; 63(2):229-38. PubMed ID: 18398615 [TBL] [Abstract][Full Text] [Related]
9. Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up. Lahaye T; Riehm B; Berger U; Paschka P; Müller MC; Kreil S; Merx K; Schwindel U; Schoch C; Hehlmann R; Hochhaus A Cancer; 2005 Apr; 103(8):1659-69. PubMed ID: 15747376 [TBL] [Abstract][Full Text] [Related]
10. Resolution of carboxylate protonation microequilibria of NTA, EDTA and related complexones. Szakács Z; Béni S; Noszál B Talanta; 2008 Jan; 74(4):666-74. PubMed ID: 18371691 [TBL] [Abstract][Full Text] [Related]
11. Elimination of imatinib mesylate and its metabolite N-desmethyl-imatinib. Bornhäuser M; Pursche S; Bonin M; Freiberg-Richter J; Jenke A; Illmer T; Ehninger G; Schleyer E J Clin Oncol; 2005 Jun; 23(16):3855-6; author reply 3857-8. PubMed ID: 15923584 [No Abstract] [Full Text] [Related]
12. Rottlerin synergistically enhances imatinib-induced apoptosis of BCR/ABL-expressing cells through its mitochondrial uncoupling effect independent of protein kinase C-delta. Kurosu T; Tsuji K; Kida A; Koyama T; Yamamoto M; Miura O Oncogene; 2007 May; 26(21):2975-87. PubMed ID: 17130834 [TBL] [Abstract][Full Text] [Related]
13. Phosphorylation levels of BCR-ABL, CrkL, AKT and STAT5 in imatinib-resistant chronic myeloid leukemia cells implicate alternative pathway usage as a survival strategy. Jilani I; Kantarjian H; Gorre M; Cortes J; Ottmann O; Bhalla K; Giles FJ; Albitar M Leuk Res; 2008 Apr; 32(4):643-9. PubMed ID: 17900686 [TBL] [Abstract][Full Text] [Related]